Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (VNDA): 17 pipeline candidates · 11 upcoming catalysts · ~8 mo cash runway · 28 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
7.5 months
D/E 0.54 · 0% dilution
Lead: Approved
17 candidates
11 upcoming, next in ~166d
0 buys · 6 sells (180d)
A transparent, data-derived signal for Vanda Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$353.0M
Cash
$54.5M
Quarterly Burn
$50.2M
Runway
7.5 mo
Revenue
$51.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (17 candidates)
| Drug | Phase |
|---|---|
| 300 mg imsidolimab | Phase 3 |
| 750 mg imsidolimab | Phase 3 |
| bysanti | Phase 3 |
| double-blind 200 mg imsidolimab | Phase 3 |
| fanapt | Approved |
| hetlioz | Approved |
| imsidolimab | Phase 3 |
| imsidolimab 750 mg iv/200 mg sc | Phase 3 |
| nereus | Phase 3 |
| open label tradipitant | Phase 3 |
Showing 10 of 17 candidates. Sign up for full pipeline.
Upcoming Catalysts (11)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Frequently asked questions
How many drug candidates are in Vanda Pharmaceuticals Inc.'s pipeline?
Vanda Pharmaceuticals Inc. (VNDA) has 17 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vanda Pharmaceuticals Inc.'s lead drug candidate?
Vanda Pharmaceuticals Inc.'s most advanced tracked candidate is 300 mg imsidolimab (Phase 3) for Generalized Pustular Psoriasis.
What is Vanda Pharmaceuticals Inc.'s next catalyst?
Vanda Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Naus" — expected December 1, 2026.
What is Vanda Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vanda Pharmaceuticals Inc. has approximately 7.5 months of cash runway.
What is Vanda Pharmaceuticals Inc.'s market capitalization?
Vanda Pharmaceuticals Inc.'s market capitalization is approximately $353.0M.
Get the full picture on Vanda Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.